Grateful for the opportunity!! Thank you for your guidance! I learned a lot through this paper!! And yes!! I am looking for a job in DC/Maryland/Northern VA! 🤗

Feels way more complicated than this (esp with TKI/sequencing) but a 2024 #NSCLC management algorithm for boards #lcsm #MedTwitter #OncTwitter

To take the right care of a patient with lung cancer takes a village! This is our Montefiore Health System Albert Einstein College of Medicine - Official village! #ArthurAvenue #Bronx Brendon Stiles Nitin Ohri Chirag Shah MD Ali Sadoughi Steven Vogl Neel Chudgar, MD

Saturday Morning Live From New York! From a Sunrise Tumor board to targeted/immunotherapies/BiTEs/ADCs + challenging cases galore and of course the best faculty/ attendees: This conference has everything! Look forward to seeing you there!

My and Dr. Kris’ car VoglNY and HaigentzNJ Steven Vogl Missak Haigentz The best raffle gifts Smores And more! Join us for #NYLung25 along with co-chair Jamie Chaft! PER

Updated treatment algorithms for breast cancer now include adjuvant ribociclib and inavolisib, along with trial names. Thrilled to see we're truly running out of space in HR+ disease—progress is here, with much more to come for all breast cancer subtypes #bcsm Dana-Farber’s Breast Oncology Center

#TumorBoardTuesday Balazs Halmos Integrity CE, LLC Roy Herbst NEJM Jackie Aredo Enriqueta Felip Patrick Forde M.Provencio Heather Wakelee 23/29 #TumorBoardTuesday 👩‍🏫Mini tweetorial 14👨‍🏫 🔑🎵KEYNOTE-671 🔸Stage II-IIIB (N2) NSCLC 🔸Periop pembro ChemoIO x 4▶️surg▶️IO v Chemo▶️surg▶️placebo 🤩Results🤩 📈OS (HR 0.73, p=0.02) 📈pCR rate (18.1% v 4.0%) 👏Finally an OS benefit 🏆FDA Approved

It was a pleasure to reviewing this excellent MRD work from the ADAURA trial led by Drs. ⁦⁦⁦Roy Herbst⁩ ⁦Thomas Wu⁩ & co. Key addition to the knowledge in resected lung cancer, primetime for MRD is getting close! #lcsm nature.com/articles/s4159…

Team Mediastinal Minds presenting at OncLive.com fellows’ forum on breaking barriers for pts w/ #lungcancer w/ brain mets. #ASCO25 Hem-Onc Fellows Network #lcsm

Spot our attendings from Montefiore Einstein Comprehensive Cancer Center at #ASCO2025🥳🥳 Our outstanding malignant-heme attending, Dr. Mendel Goldfinger, presented use of weekly decitabine and venetoclax to improve outcomes in MDS and AML patients withTP53 mutations

Montefiore in the house🥳🥳 Joined by our recent alumni Shawn and Ece❤️❤️ #reunion #traineeandearlycareer #ASCO2025 #hemeoncfellows #montefioreeinstein

I am not here saying that our Montefiore Health System #ASCO25 dinner was necessarily the best of all- although i could based on the great mango lassis/ fabulous chief fellow menu and table arrangement choices and terrific company of present and past Monte hem/oncs! But has YOUR party

Had an amazing D -1 with OncLive.com before #ASCO25 🙌. Inspired by the smart questions and teamwork of my co-fellows, and infinite gratitude for the guidance of Christine Garcia, MD, MPH our mediastinal Jedi mind, Benjamin Levy Narjust Florez, MD, FASCO Kristen A. Marrone, MD Eric K. Singhi, MD Sandip Patel MD FASCO

One-on-one mentorship is priceless! 🤩🤩 Thank you Isabel Preeshagul for the guidance in transitioning into a faculty role✨✨ #ASCO2025 #Mentorship #luckyday🍀

Continuing yearly tradition at #ASCO25 tuning in Balazs Halmos with Enriqueta Felip Julia Rotow MD at PER with Montefiore Heme Onc Fellowship fellows front and center🙋🏻‍♀️🙋🏻‍♀️ Feeling extra up-skilled in treatment options for EGFR classical ex20 and atypical mutations😎 #DoIgettograduatein3wks

Telisotuzumab adizutecan (ABBV-400, Temab-A) in #EGFR NSCLC at #ASCO25. This is a cMET ADC like Teliso-V but with a topoisomerase 1 inhibitor. Safety notable for myelosuppression, 7% pneumonitis (1 fatal). RR 63%, DOR 9.8m, PFS 10.9m.

Excellent presentation by Dr. Sukhi Padda on Lung-MAP S1900E Outcome of sotorasib for K-Ras G12C+ patients impacted by co-mutation status- in particular STK11 Adds to the evolving story on STK11 and other co-mutations that in biomarker testing for pts w advanced NSCLC we need

Periop IO– OS Data in Context 🧬 CM816: HR 0.72 | 5y 65% vs 55% #ASCO25 Patrick Forde nejm.org/doi/full/10.10… 💉 KN-671: HR 0.72 | 4y 67% vs 51% 📊 CM77T: HR 0.85 | 3y 78% vs 72% #ASCO25 👉Neoadjuvant only may do the job!!

Thank you Balazs Halmos Haiying Cheng for your mentorship and guidance! Excited to move to next chapter in DC! And Shuai Wang my cofellow/asco buddy/ future thoracic oncologist to be visited at nashville😎

Make plans for #DCLung25 - Saturday, October 4th - Washington DC - a one-day IASLC endorsed comprehensive lung cancer conference! Dr. Alfredo Addeo Alfredo Addeo MD joins from Switzerland to discuss bispecific antibodies and lung cancer. Register today! medstarhealth.org/dclung25